{
    "nct_id": "NCT04972942",
    "official_title": "Phase I Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults with High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)",
    "inclusion_criteria": "* 0-39yrs\n* T-cell ALL in second or subsequent remission (≤ 5% blasts) or relapsed T-cell LLy with complete response after re-induction therapy (including secondary malignancy)\n* Planned allogeneic stem cell transplantation with donor identified\n* Performance status ≥ 60%\n* Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\n* Meet organ function requirements\n* Signed IRB approved informed consent\nHealthy volunteers allowed\nMust have maximum age of 39 Years",
    "exclusion_criteria": "* May not have had a prior autologous or allogenic stem cell transplant\n* May not have uncontrolled, systemic infection at the time of enrollment\n* Known allergies, hypersensitivity, or intolerance to mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients\n* Must not be pregnant or actively breast feeding\n* Seropositive for HIV, hepatitis B or hepatitis C\n* COPD\n* Asthma\n* Clinically significant cardiac disease",
    "miscellaneous_criteria": ""
}